---
title: "Five-year biannual azithromycin MDA did not lower overall enteric fever seroincidence in Niger"
id: "medrxiv-2-effect-of-five-years-of-biannual-azithromycin-mass-drug-administration-on"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-effect-of-five-years-of-biannual-azithromycin-mass-drug-administration-on"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1?rss=1"
published_at: "2026-08-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Five-year biannual azithromycin MDA did not lower overall enteric fever seroincidence in Niger
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-effect-of-five-years-of-biannual-azithromycin-mass-drug-administration-on
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1?rss=1)
- **Published At:** 2026-08-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study is a secondary analysis of the MORDOR cluster-randomized, placebo-controlled trial (NCT02048007) in 30 rural communities in Dosso Region, Niger, assessing the effect of biannual mass drug administration (MDA) of **azithromycin** to children aged 1–59 months on community-level **enteric fever** seroincidence. - Dried blood spots were collected at baseline (2015) and Year 5 (2020). Samples from 1,417 children were analyzed: 423 at baseline and 994 at Year 5. - IgA and IgG antibodies against **Hemolysin E** were measured by kinetic ELISA to infer recent infection; seroincidence estimates used maximum likelihood methods calibrated to antibody kinetics from blood culture–confirmed enteric fever cases. - In placebo communities, seroincidence rose from 68.5 (95% CI 58.0–80.7) to 145.2 (95% CI 132.3–159.3) per 100 person-years between baseline and Year 5. - In azithromycin communities, seroincidence rose from 74.7 (95% CI 56.5–98.7) to 135.2 (95% CI 112.4–162.6) per 100 person-years over the same period. - The difference-in-differences for overall seroincidence between azithromycin and placebo arms was not statistically significant (−16.2; 95% CI −53.1 to 20.8). - Among children under 2 years, the increase in seroincidence was smaller in the azithromycin arm (37.5; 95% CI 1.3–73.6) than placebo (81.1; 95% CI 54.0–108.2), with a difference-in-differences of −43.7 per 100 person-years (95% CI −88.8 to −1.5 to 0.02), suggesting a possible attenuation in this youngest subgroup. - The authors conclude that enteric fever **seroincidence** in young children in rural Niger is high and rose substantially over five years; biannual azithromycin MDA did not significantly reduce community-level seroincidence overall, though a potential benefit was observed in children under 2 years. - The report underscores the importance of recent **typhoid conjugate vaccine** introduction in Niger and highlights the role of **serosurveillance** where blood culture surveillance is unavailable. - This article is a preprint (medRxiv) and has not been peer reviewed; authors report no competing interests. De-identified data will be available on OSF upon publication.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=fQaYC80Y4Lf4jbaPPU9cplCWVK0fJW48.1kKGA.GTUM-1785883400.812798-1.2.1.1-MzMg3zJZFHM6taQ1H7Jz5KVWsyZ51IXM4S1BZHB56FY) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Effect of five years of biannual azithromycin mass drug administration on enteric fever seroincidence in Niger: A randomized control trial [ View ORCID Profile](http://orcid.org/0000-0003-1886-2699)Kristen Aiemjoy, [ View ORCID Profile](http://orcid.org/0009-0005-1645-3789)Jessica Seidman, Ahmed M Arzika, Ramatou Maliki, Amza Abdou, Douglas Ezra Morrison, [ View ORCID Profile](http://orcid.org/0000-0002-5761-7437)Kristina W Lai, Denise O Garrett, Claire Munroe, Abel Gonzalez, Leah Sukri, Elodie Lebas, Catherine Cook, Benjamin F Arnold, Thomas M Leitman, Kathleen M Neuzil, Jason R Andrews, Jeremy D Keenan, [ View ORCID Profile](http://orcid.org/0000-0002-8881-1849)Richelle C Charles doi: https://doi.org/10.64898/2026.08.03.26359544 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Kristen Aiemjoy 1 University of California Davis; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristen%2BAiemjoy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aiemjoy%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKristen%2BAiemjoy%2B) * [ORCID record for Kristen Aiemjoy](http://orcid.org/0000-0003-1886-2699 "Open in new tab") * For correspondence: kaiemjoy@health.ucdavis.edu Jessica Seidman 2 Albert B Sabin Vaccine Institute: Sabin Vaccine Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2BSeidman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Seidman%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJessica%2BSeidman%2B) * [ORCID record for Jessica Seidman](http://orcid.org/0009-0005-1645-3789 "Open in new tab") Ahmed M Arzika 3 Centre de Recherche et d’Intervention en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ahmed%2B%2BM%2BArzika%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arzika%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAhmed%2B%2BM%2BArzika%2B) Ramatou Maliki 3 Centre de Recherche et d’Intervention en Santé Publique; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ramatou%2BMaliki%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maliki%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARamatou%2BMaliki%2B) Amza Abdou 4 Programme Nationale de Santé Oculaire; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amza%2BAbdou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Abdou%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmza%2BAbdou%2B) Douglas Ezra Morrison 1 University of California Davis; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Douglas%2B%2BEzra%2BMorrison%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Morrison%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADouglas%2B%2BEzra%2BMorrison%2B) Kristina W Lai 5 UC Davis: University of California Davis; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristina%2B%2BW%2BLai%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lai%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKristina%2B%2BW%2BLai%2B) * [ORCID record for Kristina W Lai](http://orcid.org/0000-0002-5761-7437 "Open in new tab") Denise O Garrett 2 Albert B Sabin Vaccine Institute: Sabin Vaccine Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Denise%2B%2BO%2BGarrett%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garrett%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADenise%2B%2BO%2BGarrett%2B) Claire Munroe 6 Massachusetts General Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claire%2BMunroe%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Munroe%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaire%2BMunroe%2B) Abel Gonzalez 6 Massachusetts General Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abel%2BGonzalez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gonzalez%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbel%2BGonzalez%2B) Leah Sukri 7 University of Maryland School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Leah%2BSukri%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sukri%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALeah%2BSukri%2B) Elodie Lebas 8 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elodie%2BLebas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lebas%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElodie%2BLebas%2B) Catherine Cook 8 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Catherine%2BCook%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cook%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACatherine%2BCook%2B) Benjamin F Arnold 8 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2B%2BF%2BArnold%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arnold%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2B%2BF%2BArnold%2B) Thomas M Leitman 8 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2B%2BM%2BLeitman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Leitman%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2B%2BM%2BLeitman%2B) Kathleen M Neuzil 7 University of Maryland School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kathleen%2B%2BM%2BNeuzil%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Neuzil%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKathleen%2B%2BM%2BNeuzil%2B) Jason R Andrews 9 Stanford University School of Medicine * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jason%2B%2BR%2BAndrews%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Andrews%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJason%2B%2BR%2BAndrews%2B) Jeremy D Keenan 8 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jeremy%2B%2BD%2BKeenan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Keenan%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJeremy%2B%2BD%2BKeenan%2B) Richelle C Charles 6 Massachusetts General Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richelle%2B%2BC%2BCharles%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Charles%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichelle%2B%2BC%2BCharles%2B) * [ORCID record for Richelle C Charles](http://orcid.org/0000-0002-8881-1849 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1271901/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1271901/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1271901/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1271901/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1271901/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract BACKGROUND Enteric fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a major cause of morbidity in low- and middle-income countries, yet burden estimation is challenging in regions without blood culture surveillance. Azithromycin is effective for treating enteric fever, and mass drug administration (MDA) to young children reduces all-cause mortality in sub-Saharan Africa, but its impact on community-level enteric fever burden is unknown. We assessed enteric fever seroincidence in rural Niger and evaluated the effect of biannual azithromycin MDA affected. PRINCIPAL FINDINGS This was a secondary analysis of the MORDOR trial ([NCT02048007](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02048007&atom=%2Fmedrxiv%2Fearly%2F2026%2F08%2F04%2F2026.08.03.26359544.atom)), a cluster-randomized, placebo-controlled study in 30 communities in Dosso Region, Niger. Children aged 1–59 months received biannual azithromycin or placebo. Dried blood spots collected at baseline (2015) and Year 5 (2020) were tested for IgA and IgG antibodies against Hemolysin E using kinetic ELISA. Seroincidence was estimated using maximum likelihood methods based on antibody kinetics from blood culture-confirmed enteric fever patients. Samples from 1,417 children were analyzed (423 baseline; 994 Year 5). Overall seroincidence approximately doubled from baseline to Year 5, increasing from 68.5 (95% CI 58.0–80.7) to 145.2 (95% CI 132.3–159.3) per 100 person-years in placebo communities and from 74.7 (95% CI 56.5–98.7) to 135.2 (95% CI 112.4–162.6) in azithromycin communities, with no significant difference between arms (difference-in-differences −16.2; 95% CI -53.1-20.8 ). Among children ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The trial was approved by institutional review boards at the University of California, San Francisco and the Niger Ministry of Health. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability De-identified data will be available upon publication in OSF Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.03.26359559v1 "Adults who suspect they may be autistic or have ADHD show corresponding neurodevelopmental polygenic effects")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.03.26359546v1 "Non-Participation Undermines Mass Drug Administration Effectiveness and Sustains Urogenital Schistosomiasis Transmission in an Endemic Community in Ghana.") Posted August 04, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/04/2026.08.03.26359544.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.03.26359544v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/04/2026.08.03.26359544.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Effect of five years of biannual azithromycin mass drug administration on enteric fever seroincidence in Niger: A randomized control trial Kristen Aiemjoy, Jessica Seidman, Ahmed M Arzika, Ramatou Maliki, Amza Abdou, Douglas Ezra Morrison, Kristina W Lai, Denise O Garrett, Claire Munroe, Abel Gonzalez, Leah Sukri, Elodie Lebas, Catherine Cook, Benjamin F Arnold, Thomas M Leitman, Kathleen M Neuzil, Jason R Andrews, Jeremy D Keenan, Richelle C Charles medRxiv 2026.08.03.26359544; doi: https://doi.org/10.64898/2026.08.03.26359544 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent
## Related Clinical Research

- [Extracellular microRNAs in serum and EVs as candidate biomarkers for Chlamydia trachomatis reinfec](https://medichelpline.com/clinical-feed/plos-one-15-evaluation-of-extracellular-micrornas-as-potential-biomarker-candidates-for.md)
- [Genomic epidemiology and emerging antimicrobial resistance in Salmonella Paratyphi A from Australi](https://medichelpline.com/clinical-feed/medrxiv-13-genomic-epidemiology-and-emerging-antimicrobial-resistance-profiles-of.md)
- [Azithromycin versus doxycycline with beta-lactams for hospitalised community-acquired pneumonia: t](https://medichelpline.com/clinical-feed/bmj-open-4-azithromycin-versus-doxycycline-in-hospitalised-adult-patients-with-community.md)
- [In vitro activity of gepotidacin combinations against Neisseria gonorrhoeae isolates](https://medichelpline.com/clinical-feed/pubmed-42390436.md) (DOI: 10.1128/aac.00059-26)
- [Antimicrobial resistance and whole-genome sequencing of Neisseria gonorrhoeae isolates, Bangrak ST](https://medichelpline.com/clinical-feed/pubmed-42550164.md) (DOI: 10.1093/jac/dkag260)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.